IBDEI1OB ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28432,2)
 ;;=^5002284
 ;;^UTILITY(U,$J,358.3,28433,0)
 ;;=D50.0^^112^1421^3
 ;;^UTILITY(U,$J,358.3,28433,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28433,1,3,0)
 ;;=3^Anemia d/t Blood Loss (Chronic)
 ;;^UTILITY(U,$J,358.3,28433,1,4,0)
 ;;=4^D50.0
 ;;^UTILITY(U,$J,358.3,28433,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,28434,0)
 ;;=E11.21^^112^1421^18
 ;;^UTILITY(U,$J,358.3,28434,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28434,1,3,0)
 ;;=3^DM Type 2 w/ Nephropathy
 ;;^UTILITY(U,$J,358.3,28434,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,28434,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,28435,0)
 ;;=E11.22^^112^1421^8
 ;;^UTILITY(U,$J,358.3,28435,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28435,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic CKD
 ;;^UTILITY(U,$J,358.3,28435,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,28435,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,28436,0)
 ;;=E11.29^^112^1421^19
 ;;^UTILITY(U,$J,358.3,28436,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28436,1,3,0)
 ;;=3^DM Type 2 w/ Other Diabetic Kidney Complication
 ;;^UTILITY(U,$J,358.3,28436,1,4,0)
 ;;=4^E11.29
 ;;^UTILITY(U,$J,358.3,28436,2)
 ;;=^5002631
 ;;^UTILITY(U,$J,358.3,28437,0)
 ;;=E11.311^^112^1421^20
 ;;^UTILITY(U,$J,358.3,28437,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28437,1,3,0)
 ;;=3^DM Type 2 w/ Unspec Diabetic Retinopathy w/ Macular edema
 ;;^UTILITY(U,$J,358.3,28437,1,4,0)
 ;;=4^E11.311
 ;;^UTILITY(U,$J,358.3,28437,2)
 ;;=^5002632
 ;;^UTILITY(U,$J,358.3,28438,0)
 ;;=E11.319^^112^1421^21
 ;;^UTILITY(U,$J,358.3,28438,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28438,1,3,0)
 ;;=3^DM Type 2 w/ Unspec Diabetic Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,28438,1,4,0)
 ;;=4^E11.319
 ;;^UTILITY(U,$J,358.3,28438,2)
 ;;=^5002633
 ;;^UTILITY(U,$J,358.3,28439,0)
 ;;=E11.40^^112^1421^10
 ;;^UTILITY(U,$J,358.3,28439,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28439,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,28439,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,28439,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,28440,0)
 ;;=E11.41^^112^1421^9
 ;;^UTILITY(U,$J,358.3,28440,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28440,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Mononeuropathy
 ;;^UTILITY(U,$J,358.3,28440,1,4,0)
 ;;=4^E11.41
 ;;^UTILITY(U,$J,358.3,28440,2)
 ;;=^5002645
 ;;^UTILITY(U,$J,358.3,28441,0)
 ;;=E11.42^^112^1421^13
 ;;^UTILITY(U,$J,358.3,28441,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28441,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,28441,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,28441,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,28442,0)
 ;;=E11.43^^112^1421^7
 ;;^UTILITY(U,$J,358.3,28442,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28442,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,28442,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,28442,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,28443,0)
 ;;=E11.51^^112^1421^11
 ;;^UTILITY(U,$J,358.3,28443,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28443,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Peripheral Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,28443,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,28443,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,28444,0)
 ;;=E11.52^^112^1421^12
 ;;^UTILITY(U,$J,358.3,28444,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28444,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,28444,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,28444,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,28445,0)
 ;;=E11.621^^112^1421^14
 ;;^UTILITY(U,$J,358.3,28445,1,0)
 ;;=^358.31IA^4^2
